Cencora (COR) valuation
Cencora P/E ratio history
Cencora trades at 24.6 times its earnings over the last twelve months and 17.1 times the earnings analysts expect over the next twelve.
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Cencora valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| CencoraCOR | — | 24.6 | 17.1 | — |
| Cardinal HealthCAH | $58.7B | 34.6 | — | 0.2 |
| CignaCI | $78.9B | 12.3 | 9.3 | 0.3 |
| CenteneCNC | $33.8B | 22.7 | 12.6 | 0.2 |
| CVS HealthCVS | $115B | 23.8 | 10.9 | 0.3 |
| Quest DiagnosticsDGX | $27.8B | 25.1 | 21.3 | 2.4 |
| DaVitaDVA | $12.0B | 13.9 | 11.4 | 0.8 |
| Elevance HealthELV | $91.2B | 17.8 | 14.0 | 0.5 |
| HCA HealthcareHCA | $102B | 15.7 | 15.3 | 1.3 |
| Peer median | 20.3 | 12.6 | 0.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: COR returns
No forecast, no recommendation. This page describes Cencora from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.